Aviamarin tab. 50mg # 10

Release form, composition and packaging

Tablets are white or almost white, round, flat-cylindrical, beveled and scored.

1 tab.

Dimenhydrinate 50 mg

microcrystalline cellulose, povidone (kollidone 30), crospovidone, mannitol, colloidal silicon dioxide (aerosil), magnesium stearate.

5 pieces.

- contour cell packaging (1) - cardboard packs.

5 pieces.

- contour cell packages (2) - cardboard packs.

10 pieces.

- contour cell packaging (1) - cardboard packs.

10 pieces.

- contour cell packages (2) - cardboard packs.

pharmachologic effect

Blocks histamine H1 receptors and m-cholinergic receptors of the central nervous system.

Inhibits the vestibular apparatus of the inner ear, acting primarily on the otoliths, in high doses - on the semicircular canals.

It has antiemetic, anorexigenic, sedative effect, eliminates dizziness.

Pharmacokinetics

Absorption and distribution

After oral administration, dimensionhydrinate is well absorbed and distributed to organs and tissues.

The effect of the drug manifests itself in 15-30 minutes and lasts for 3-6 hours. About 78% of dimensionhydrinate binds to blood plasma proteins.

Metabolism and excretion

Dimenhydrinate is metabolized in the liver and is almost completely excreted in the urine within 24 hours. Small amounts are excreted in breast milk.

T1 / 2 of dimensionhydrinate is about 3.5 hours.

Indications for use

- motion sickness (sea, car and air sickness)

- prevention and treatment of symptoms of vestibular and labyrinth disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by anticancer therapy

- Meniere's disease.

Contraindications for use

- hypersensitivity to drug components

- epilepsy

- acute exudative and vesicular dermatoses

- children under 3 years old

- I trimester of pregnancy

- the period of breastfeeding.

Carefully

Convulsive syndrome, angle-closure glaucoma, prostatic hyperplasia, bronchial asthma, cardiovascular disease, hyperthyroidism, stenosing peptic ulcer, pyloroduodenal obstruction and bladder neck obstruction.

Dosage regimen

Inside, before meals.

Motion sickness (sea, car and air sickness)

Children aged 3 to 6 years: 1 / 4-1 / 2 tablets 2-3 times / day.

Children aged 7-12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab.

2-3 times / day

Prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by anticancer therapy

Children aged 3 to 6 years: 1 / 4-1 / 2 tablets 2-3 times / day.

Children aged 7-12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab.

2-3 times / day

Meniere's disease

Children aged 3 to 12 years: 1 / 2-1 tablet 2-3 times / day.

Children over 12 years old and adults: 1-2 tab.

2-3 times / day

The maximum daily dose for adults should not exceed 7 tablets.

For the prevention of kinetosis, 1-2 tablets should be taken 30 minutes before the trip.

The duration of the drug and the possibility of repeating the course of treatment - in agreement with the doctor.

Overdose

Overdose symptoms: dry mouth, nose and throat, facial redness, slow and labored breathing, confusion, in children - convulsions, hallucinations.

If these symptoms appear, an urgent need to consult a doctor.

Treatment: gastric lavage with a suspension of activated carbon (20-30 g), the appointment of a saline laxative (10-15 g of sodium sulfate), symptomatic therapy, for convulsions in children - phenobarbital (5-6 mg / kg), diazepam.

Side effect

Definition of categories of frequency of adverse reactions:

Name ENG

AVIAMARIN

Clinical and pharmacological group

The drug used for pathology of the vestibular apparatus

ATX code

Other antihistamines for systemic use

Dosage

50mg

Structure

1 tablet contains: active substance: dimensionhydrinate 50.0 mg

excipients: microcrystalline cellulose 40.0 mg, povidone 4.0 mg, crospovidone 10.0 mg, mannitol 90.0 mg, colloidal silicon dioxide (aerosil) 4.0 mg, magnesium stearate 2.0 mg.

Indications

Sea and air sickness.

Prevention and treatment of symptoms of vestibular and labyrinthine disorders (dizziness, nausea, vomiting), with the exception of symptoms caused by anticancer therapy.

Symptomatic therapy for Meniere's disease.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

INN / Active ingredient

dimensionhydrinate

Contraindications

Hypersensitivity to dimensionhydrinate or other components of the drug, children under 6 years of age, breastfeeding period.

Specifications

Category

Vomiting, nausea

Scope of the drug

Gastrointestinal tract

Release form

Tablet

Manufacturer country

Russia

Package quantity, pcs

ten

Scope of application

Gastroenterology

Minimum age from

6 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Obolenskoe FP

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

H1-histamine receptor blocker

Anatomical and therapeutic characteristics

R06AX Other antihistamines for systemic use

Dosage form

Pills

Expiration date in days

1095

The target audience

Children

Package weight, g

ten

Mode of application

:

Inside, before meals.

To prevent motion sickness, the first dose should be taken 30-60 minutes before the start of movement.

< br> Children aged 6-12 years: 1 / 2-1 tablet (25-50 mg) every 6-8 hours, but not more than 3 tablets (150 mg) within 24 hours.

< br> Adults and children 12 years and older: 1-2 tablets (50-100 mg) every 4-6 hours, but not more than 8 tablets (400 mg) within 24 hours.

< br>

Information on technical characteristics, delivery set, country of manufacture